Trial Profile
An Open-label study to evaluate the effect of drug-drug interaction on the outcomes of the Cannabidiol (Epidiolex®) treatment in patients with Epilepsy
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 13 Aug 2020
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary) ; Clobazam; Eslicarbazepine acetate; Rufinamide; Topiramate; Zonisamide
- Indications Epilepsy
- Focus Expanded access; Therapeutic Use
- 10 May 2018 New trial record
- 27 Apr 2018 Results assessing changes in seizure frequency (SF) and severity (Chalfont Seizure Severity Scale; CSSS) and durability of the response to cannabidiol presented at the 70th Annual Meeting of the American Academy of Neurology
- 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology